1,442 results on '"Ducreux M"'
Search Results
2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
3. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer
4. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
6. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer
7. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
8. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study
9. MSR75 Correlate: Assessing Dose Effect Using Targeted Maximum Likelihood Estimation (TMLE)
10. Gender medicine and oncology: report and consensus of an ESMO workshop
11. Management of colorectal peritoneal metastases: Expert opinion
12. Accord d’experts français pour la prise en charge des métastases péritonéales de cancers colo-rectaux
13. Is intra-arterial hepatic chemotherapy painful?
14. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial
15. Imagerie des tumeurs pancréatiques endocrines
16. Imaging of neuroendocrine tumors of the pancreas
17. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona
18. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
19. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV
20. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
21. Oncologie interventionnelle des métastases hépatiques et pulmonaires du cancer colorectal : état de l’art
22. Interventional oncology for liver and lung metastases from colorectal cancer: The current state of the art
23. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma
24. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin
25. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
26. Métastases hépatiques, pulmonaires et péritonéales des cancers colorectaux
27. Liver, lung and peritoneal metastases in colorectal cancers: Is the patient still curable? What should the radiologist know
28. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
29. SO-4 Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma
30. SO-5 Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: An analysis of 4518 individual patients and 22 trials
31. SO-1 Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma
32. Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers
33. Reply to the Letter to the Editor ‘Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten’ (in regard to “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”) by Huguet et al.
34. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
35. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs
36. Central retroperitoneal recurrences from colorectal cancer: Are lymph node and locoregional recurrences the same disease?
37. Disseminated and circulating tumor cells in gastrointestinal oncology
38. Selecting the right chemotherapy in first-line advanced squamous cell carcinoma of the anus
39. Accès aux tests génétiques en oncologie
40. Chirurgie à visée curative des métastases péritonéales
41. Chimiothérapie des métastases d’origine colorectale jamais résécables : stratégie multiligne, thérapies ciblées
42. Valorization of unsaturated dicarboxylic acids obtained from bio-fermentation of organic municipal wastes
43. Pancreatic cancer treatment and research: an international expert panel discussion
44. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
45. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial
46. IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
47. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
48. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
49. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
50. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.